No General Anesthesia, No Overnight Stay: NBI-Guided Diode Laser Ablation Offers a Minimally Invasive Option for Recurrent Low-Grade Bladder Cancer
en-GBde-DEes-ESfr-FR

No General Anesthesia, No Overnight Stay: NBI-Guided Diode Laser Ablation Offers a Minimally Invasive Option for Recurrent Low-Grade Bladder Cancer

18/11/2026 HEP Journals

Low-grade non-muscle-invasive bladder cancer progresses rarely but recurs in 50%–70% of cases, and transurethral resection carries perioperative risks and inpatient burden. In this single-center study, all ablations were performed in the outpatient clinic under local anesthesia with a diode laser, routine cold-cup biopsies, and systematic NBI; patients with positive cytology, high-grade disease, carcinoma in situ, or muscle-invasive cancer were excluded. Over a mean follow-up of 24.2 ± 14.7 months, 44 of 71 patients (62%) recurred. Recurrence was associated with younger age (median 52.5 vs. 65 years, p < 0.001) and more than three original tumors (40.9% vs. 11.1%, p = 0.01), and multivariable analysis identified age (OR = 0.79), comorbidities, follow-up duration, and number of ablated tumors (OR = 2.50) as independent predictors.

No patient progressed to muscle-invasive disease, and there were no cases of bladder perforation, significant hematuria, urinary retention, or hospital admission. The authors conclude that NBI-guided diode laser ablation is safe and well tolerated, offering effective local control without general anesthesia or hospitalization, while noting that the retrospective single-center design, small sample size, and lack of a TURBT comparator require prospective validation.

The work titled “Narrow band imaging‐guided diode laser ablation in recurrent low‐grade non‐muscle‐invasive bladder cancer” was published in UroPrecision (published on May 7, 2026).
doi:10.1002/uro2.70069
Archivos adjuntos
  • Image: Recurrence-free survival (RFS).
18/11/2026 HEP Journals
Regions: Asia, China
Keywords: Science, Life Sciences

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonios

We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet
AlphaGalileo is a great source of global research news. I use it regularly.
Robert Lee Hotz, LA Times

Trabajamos en estrecha colaboración con...


  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2026 by DNN Corp Terms Of Use Privacy Statement